DRG-MAOB-2 Selective MAO-B Inhibitor for Isoform-Specific Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Parkinson's and Alzheimer's are long-term and economically challenging, and there is a need for MAO-B selective inhibitors due to the similarity between MAO-A and MAO-B isoforms, making it difficult to develop effective drugs.
Innovation Solution
A novel compound, DRG-MAOB-2, is developed as a selective inhibitor of MAO-B, which can be formulated into pharmaceutical compositions for various routes of administration, including oral, parenteral, and topical, to treat neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MAO-B selective inhibition is pursued to treat neurodegenerative diseases, then therapeutic effectiveness is improved, but drug development difficulty increases due to 70% sequence identity between MAO-A and MAO-B isoforms
Solution Approach 1:
The patent applies local quality by designing a molecule with specific functional groups (aromatic ring with hydroxyl group, basic nitrogen-containing group) that interact with specific local regions of the MAO-B active site. The compound's structural features are optimized to fit the unique local environment of MAO-B's binding pocket, exploiting subtle differences in amino acid residues at the active site to achieve selective inhibition despite overall sequence similarity
Solution Approach 2:
The patent employs parameter changes by modifying molecular parameters such as the pKa of the basic nitrogen-containing group and the spatial arrangement of functional groups. These parameter adjustments allow the compound to optimize its interaction with MAO-B's active site, achieving selective binding through altered electrostatic interactions and hydrogen bonding patterns that differ between MAO-A and MAO-B isoforms
2Reliability
If MAO enzyme inhibition is used to increase neurotransmitter substances in synaptic spaces, then treatment effectiveness for neurodegenerative diseases is improved, but long-term treatment duration and economic burden increase
Solution Approach 1:
The patent applies the taking out principle by extracting and targeting only the MAO-B isoform specifically, rather than inhibiting both MAO-A and MAO-B. This selective extraction of the therapeutic target allows for more precise intervention in neurotransmitter metabolism, potentially achieving better therapeutic outcomes with reduced side effects and optimized treatment duration
Solution Approach 2:
The patent uses the compound of formula I as an intermediary substance that mediates between the administered drug and the MAO-B enzyme. This intermediary molecule provides sustained inhibition of MAO-B activity, maintaining neurotransmitter levels in synaptic spaces over extended periods and potentially reducing the frequency of administration required
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DRG-MAOB-2 demonstrates a 9-fold higher potency in inhibiting MAO-B compared to MAO-A, providing a therapeutic benefit for neurodegenerative diseases such as Parkinson's and Alzheimer's.
Implementation Method 1
DRG-MAOB-2 demonstrates a 9-fold higher potency in inhibiting MAO-B compared to MAO-A, providing a therapeutic benefit for neurodegenerative diseases
Data Source
AI summary
The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MAO-B.